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Previously bis(5-amidino-2-benzimidazolyl)-
methane (BABIM) was identified as a strong inhibi-
tor of the multisystem inflammatory disease induced
in Lewis rats by injection of streptococcus group A
cell wall-derived peptidoglycan polysaccharide (PG-
APS). A BABIM derivative, trans-bis(5-amidino-2-
benzimidazolyl)ethene (BBE), has attracted atten-
tion because ofstriking qualitative and quantitative
differences in its activities when compared with the
parent compound BBE could control destructive tib-
ial osteitis and necrotizing granulomatous splenitis
and hepatitis, regardless if given in a preventive or
curative mode. The compound had little effect on
synovitis, however. BABIM, on the other hang was
active against synovitis and osteitis, but not against
splenic granuloma formation. To be effective, it
needed to be applied in a preventive mode. BBE
caused a characteristic enlargement ofPG-APS-laden
splenic and hepatic macrophages suggesting that
those cells represent targets of the inhibitor. BBE may
be a powerful tool for the study of granulomatous
lesions (Am JPathol 1991, 139:921-931)
The authors previously discovered that bis(5-amidino-2-
benzimidazolyl)methane (BABIM) is a powerful anti-
inflammatory agent.1' 2 The test model used was the
Lewis rat in which a single systemic application of puri-
fied streptococcus group-A cell-wal-derived peptidogly-
can polysaccharide (PG-APS) leads to early (days 1-3)
development of synovitis, destructive osteitis, and gran-
ulomatous splenitis and to late appearance (day 9) of
granulomatous hepatitis. Uninterrupted daily injections of
BABIM, when given onward from day-2 of the experi-
ment, were able to suppress or ameliorate all those re-
sponses. The effect on the splenic lesions was only short-
lived, however. The inhibitory potency of the compound
raised the question whether its mechanism of action
might be tied to its other known activity, i.e., its ability to
block arginine- and lysine-directed proteases.34 Sus-
ceptible enzymes would include incompletely character-
ized cell-associated trypsinlike proteases, as well as
thrombin, plasmin, and urokinase-type plasminogen ac-
tivator all of which are known to be involved in inflamma-
tion.110 To identify such a protease target, 12 additional
bis-benzimidazoles have been investigated for their an-
tiinflammatory effectiveness. Besides establishing struc-
ture-activity relationships, the study has shown an excit-
ing new compound, trans-bis(5-amidino-2-
benzimidazolyl)ethene (BBE). The drug is exceptional in
its blockage of granulomatous lesions and its ability to act
in a preventive as well as curative mode. Furthermore, it
induces highly characteristic morphologic changes in
splenic and hepatic macrophages.
Materials and Methods
Synthesis of Benzimidazoles
Table 1 lists the structures and formulas of the com-
pounds tested, and it also includes the inhibition con-
stants (K,) for trypsin and thrombin.
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No. RX R2 X Formula Trypsin Thrombin
1 (BABIM) Am Am CH2 C17H16N8 4HCI 2H20 0.017 4.15
2 Am Am (CH2)2 C18H18N8 4HCI 2H20 4.7 11.6
3 (BBE) Am Am CH = CH C18H16N8 4HCI H20 5.0 1.6
4 Am Am (CH2)3 C19H20N8 4HCI 2H20 27.8 79.0
5 Am Am (CH2)4 C20H22N8 4HCI 1.5H20 2.9 14.9
6 Am Am (CH2)5 C21H24N8 C2H50H 3H20 9.5 9.9
7 Am Am (CH2)6 C22H26N8 4HN03 2H20 5.9 4.3
8 Am H CH2 C16H14N6 3HCI 0.39 20.7
9 H H CH2 C15H12N4 2HCI 0.3H20 >1000 >500
10 CH2NH2 CH2NH2 CH2 C17H18N6 2HCI 1.6H20 172 >200
11 Im Im CH2 C21H20N8 2.7HCI 2.8H20 >1000 >500
12 Im Im (CH2)2 C22H22N8 4HCI 617 >1000
13 Im Im (CH2)3 C23H24N8 4HCI >1000 >1000
Am = amidino group, C NH2; Im = imidazoline group, NNHN H
The synthesis and physical data for compound num-
bers 1 through 4, 6, 7, and 12 have been described.3
Compound number 13 was a gift from H. Loewe, Ho-
echst AG, Germany. Compound numbers 5 and 9 were
synthesized according to similar methods as previously
described.3 Compound number 5 was prepared by the
condensation of 3,4-diaminobenzamidine hydrochloride
with the bis-iminoether obtained from 1 ,4-dicyanobutane.
The purified product, 1,4-bis(5-amidino-2-
benzimidazolyl)butane, had a melting point of 2650C.
Purity (>98%) and structure were confirmed by elemen-
tal analysis (C,H,N), 300 MHz nuclear magnetic reso-
nance spectrometry (NMR) and high-pressure liquid
chromatography (HPLC).11 Compound number 9 was
similarly prepared by the condensation of o-phenylene-
diamine with the bis-iminoether obtained from malononi-
trile. The purified product, bis(2-benzimidazolyl)methane,
had a melting point of 3150C. Purity (>98%) and structure
of the product were determined by elemental analysis
(C,H,N), HPLC and NMR.
Compound numbers 10 and 1 1 were synthesized
from bis(5-cyano-2-benzimidazolyl)methane. For com-
pound number 10, the starting dinitrile3 was reduced
over platinum oxide at ambient temperature and 40 psi of
hydrogen in a Parr hydrogenator to give the desired
product, bis(5-aminomethyl-2-benzimidazolyl)methane.
Compound number 11 was synthesized by converting
the dinitrile to the corresponding diimidate followed by
reaction of the intermediate with ethylenediamine to give
the desired product, bis(5-imidazolyl-2-
benzimidazolyl)methane. The melting points of com-
pound numbers 10 and 11 were 264°C and 2770C, re-
spectively. The purity (>97%) and structures of both
compounds were determined by elemental analysis,
NMR and HPLC.
Compound number 8 was prepared in three steps,
the first one being the condensation of o-phenylenedi-
amine with cyanoacetamide to yield 2-cyanomethylben-
zimidazole. The second step was the acid hydrolysis of
the nitrile group to give a-(2-benzimidazolyl)acetic acid.
The acid was condensed with diaminobenzimidine in
polyphosphoric acid to give the desired product, (5-
amidino-2-benzimidazolyl)-(2-benzimidazolyl)methane,
melting point 285°C. Purity (> 96%) and structural con-
firmation were determined in the previously described
manner.
Streptococcal Cell-wall Fragments
Purified cell walls were prepared by a modification of a
previously described method.12 Disruption of group A,
type 3, strain 58 streptococci was carried out for 5 min-
utes in a Dyno-Mill (Glen Mills, Inc., Maywood, NY) kept at
40C. The glass beads were removed by coarse filtration,
and any remaining intact streptococci were collected by
low-speed centrifugation. The cell fragments were ob-
tained by centrifugation for 30 minutes at 30,000 x g. The
washed cell walls were extracted three times at 560C with
2% SDS in phosphate-buffered saline (PBS) of pH 7.0,
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washed again repeatedly, first with PBS and then with
distilled water, lyophilized, and stored at 40C.
Before each experiment, the lyophilized cell walls
were resuspended in saline and sonicated for 35 minutes
at 40C. The resultant preparation was centrifuged for 30
minutes at 10,000 x g, and the supernatant was passed
through a Millipore filter (0.45 ,um) to remove any trace of
whole bacteria or cell-wall aggregates. This final prepa-
ration was kept at 40C until use. Aseptic techniques were
used throughout.
Determination of Inhibition Constants (K,
Values)
Ki values were obtained from published records for pre-
viously established inhibitors34 and were newly deter-
mined for the remaining compounds. Target enzymes
included trypsin and thrombin, and in some instances,
also urokinase and plasmin. Conveniently available chro-
mogenic substrates were employed in the assays, and
initial reaction velocities at 37°C were plotted according
to Dixon13 to obtain the inhibition constants. Details of the
methods have been published.414 In short, all tests were
carried out at pH 8.1, except with plasmin in which a pH
of 7.6 was chosen. a-N-Benzoyl-DL-arginine-p-
nitroanilide (Sigma, St. Louis, MO) was the substrate
used with trypsin, thrombin and plasmin, whereas L-py-
roglutamyl-glycyl-L-arginine-p-nitroanilide (KABI VIT-
RUM, Stockholm, Sweden) was chosen for urokinase.
Lyophilized bovine thrombin was a product of Armour
Pharmaceutical Co., Chicago, Illinois. Lyophilized bovine
trypsin was obtained from Sigma, St. Louis, Missouri, hu-
man plasmin was obtained from KABI VITRUM, Stock-
holm, Sweden, and human urokinase (Abbokinase) was
received from Abbott Laboratories, North Chicago, Illi-
nois. The enzymatic release of p-nitroaniline was followed
spectrophotometrically. All determinations were carried
out in triplicate.
period specified. The drug was dissolved in 0.5 ml pyro-
gen-free saline and was injected into the tail vein under
light ether anesthesia.
Histologic Examination and Scoring of the
Lesions
The animals were killed with an overdose of carbon di-
oxide. Spleen and liver were expeditiously removed and
weighed, and pieces of both organs were submitted for
histologic evaluation. The hind legs were amputated
through the mid femur, skinned, fixed, decalcified, and
then divided into a proximal piece containing the knee
joint and proximal tibia and a distal piece including ankle
and foot joints. All tissues were stained with H&E and with
periodic acid Schiff (PAS) after diastase digestion. The
severity of the synovitis in ankle and knee joints was
judged separately on a scale of 0 to 4 according to the
density of the inflammatory infiltrate, the degree of syno-
vial-lining-cell hyperplasia and the amount of intraarticu-
lar exudate. For each animal, only one extremity was
rated and the values of knee and ankle joints were com-
bined for the total synovitis score. The extent of the gran-
ulomatous disease in the spleen was ranked by one of
two systems. One, which was designed for early disease
and identified as "granuloma score," considered the
number of granulomata as well as the size of the area of
destruction, whereas the other, which was designed for
late disease, was based only on the area of parenchymal
replacement. The number of granulomata in the liver per
given area was determined with the help of a Zeiss Vid-
eoplan computer image analyzer (Carl Zeiss, Germany).
The osteitis in the distal tibial metaphysis and epiphysis
was graded on a scale of 0 to 4 taking into consideration
the density of the intraosseous inflammatory infiltrate and
the degree of destruction of medullary and cortical bone
and of the epiphyseal and joint cartilage. The reparative
bone score, from 0 to 4, is an expression of the degree of
healing of the distal tibial defect by newly formed trabec-
ular bone.
Animals
Female Lewis rats (Charles River Breeding Colonies,
Wilmington, MA) with an average body weight of 145 g
were used for all animal experiments under specific
pathogen-free conditions. They were kept on an unre-
stricted diet of laboratory chow and water. Disease was
initiated by a single intraperitoneal injection of 0.5 ml of
the PG-APS suspension described earlier. The amount of
streptococcal cell-wall material was equal to 15 ,ug of
rhamnose equivalent per gram of body weight. Control
animals received PBS only. Treatment with inhibitor in-
volved single daily injections of the test agent for the time
Statistical Analysis
Student's t-test was employed to evaluate the statistical
significance of the difference between two means.
Results
Structure-Activity Relationships
In this study, 12 additional BABIM-related bis-
benzimidazoles were evaluated for their ability to sup-
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Figure 1 M1Aetaphysis and ep(phvsis of the distal tibia 2 weeks after
s.stemic PG-ANS application. A: Vehicle treatment: Extensive destruc-
tion ofbone and epiphyseal cartilage. B: BBE treatment daily during
the second week (10 mg/kg body weight/day): Neuw bone hasfilled in
the earlier area of destruction. Inflammation has disappeared. C:
BEE treatment during both weeks of the experiment (5 mg/kg body
weight/day). No evidence of disease in the tibia (Ii&i, x30).
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press PG-APS-induced disease. The test animals re-
ceived five consecutive daily injections of inhibitor. The
first dose was given immediately before the streptococ-
cal cell-wall fragments and the last dose was given 24
hours before sacrifice. In previous experiments, 5-day
period were long enough for the rats to develop synovitis,
tibial osteitis, and granulomatous disease in the spleen.
The only important facet that could not be studied under
this time restraint was granulomatous hepatitis, which
would appear about 4 days later.2 The daily dose of in-
hibitor was set at 10 mg/kg body weight, except in those
cases in which the amount had to be reduced because
of solubility problems. In each separate experiment, one
to four of the compounds were examined simultaneously.
Three types of controls were always included: animals
that had received neither PG-APS nor inhibitor; animals
that had received PG-APS, but no inhibitor; and animals
that had received PG-APS and BABIM. The latter two
controls ensured the reproducibility of the responses.
Toxicity was also evaluated for each inhibitor. The indi-
vidual groups were made up of six animals, except for
the first type of control where n was four.
As can be seen from their molecular structures in Ta-
ble 1, all inhibitors shared the presence of two benzimid-
azole moieties with BABIM. Variations from the parent
compound resulted from modification of the central link-
ing chain and/or replacement of one or both amidino
groups. Table 2 contains the data on the ability of the
compounds to reduce synovitis, destructive osteitis in the
distal tibia, and splenic disease. BABIM was effective in
blocking the first and second response, but showed no
significant amelioration of the third. In previous studies,
BABIM had caused a mild reduction in granulomatous
splenitis on day 5,2 but this variance with the current find-
ings is explained by the fact that BABIM treatment in
those cases was begun 2 days before PG-APS injection.
Four compounds (nos. 4-7), which differed from
BABIM only by the length of their central carbon chain,
followed the same general pattern of inhibition as BABIM,
although they did not match its potency. The two-carbon
chain derivative, no. 2, was able not only to reduce syn-
ovitis and osteitis, but also to diminish splenic enlarge-
ment and granuloma formation. Compounds no. 10 and
12 were distinguished chiefly by their reductive influence
on splenic weight which histologically was the result of a
decrease of the immune response. Compound no. 3
(BBE) finally, the ethene derivative of BABIM, stood out
by its ability to achieve the greatest reduction in spleen
weight and to block completely any granulomatous re-
sponse in that organ. BBE also effected a modest de-
crease in osteitis, but did not alter the severity of the syn-
ovitis.
A comparison of the antiproteolytic potency of the
compounds, as reflected by the Ki values in Table 1, with
the anti-synovitis or anti-granuloma activity, as registered
in Table 2, did not show any correlation. Compound 4, for
example, could ameliorate synovitis, whereas number 8
was devoid of such activity despite possessing lower Ki
values than number 4 against trypsin as well as thrombin.
A similar case can be made against a role for trypsin and
thrombin inhibitors in granulomatous splenitis. Thus,
number 2 is a weaker inhibitor than number 1 for trypsin
and thrombin, but still outranked the latter in its ability to
control splenitis.
Table 2. Inbibitory Effect ofBenzimidazoles on PG-APS-induced Synoviti, Tibial Osteitis, and Splenic Enlargement and
Granulomatous Disease
Spleen
Synovitis Tibial osteitis Weight* Granuloma
Compound no. score 0-8 score 0-4 mg/100g b.w. score 0-4
No inhibitor 3.21 ± 1.15 1.76 ± 0.95 770 ± 78 2.13 ± 0.52
1 (BABIM) 0.67 ± 0.83 0.04 ± 0.07 646 ± 133 2.27 ± 1.01
2t 1.48 ± 0.96 0.27 ± 0.2 594 ± 55 0.90 ± 0.5
3 (BBE) 3.50 ± 0.71 0.71 ± 0.81 398 ± 17 0
4 1.14 ± 0.93 1.27 ± 0.96 740 ± 140 1.77 ± 0.41
5t 0.88 ± 0.52 0.75 ± 0.87 743 ± 43 2.00 ± 0
6 1.13 ± 0.86 0.75 ± 0.86 640 ± 114 1.92 ± 0.8
7t 0.83 ± 1.81 0.25 ± 0.61 603 ± 73 2.02 ± 1.23
8 3.38 ± 1.05 1.17 ± 0.82 690 ± 169 1.88 ± 1.08
9 2.92 ± 1.93 1.42 ± 1.56 602 ± 116 1.43 ± 0.82
10 1.71 ± 0.87 0.33 ± 0.52 447 ± 77 1.15 ± 0.95
11 3.00 ± 0.40 1.00 ± 1.55 709 ± 138 1.78 ± 0.53
12 2.33 ± 0.61 0.92 ± 1.43 555 ± 56 1.35 ± 0.70
13 3.00 ± 1.95 0.33 ± 0.82 673 ± 1.04 2.20 ± 1.10
In 24 rats that had received neither PG-APS nor inhibitor the spleen weight was 235 + 17 mg/100 g body weight.
t Drug dose reduced to 7.5 mg/100g body weight.
There were 42 rats in the control groups which had received only PG-APS. There were 41 rats in the groups which had received BABIM as
well as PG-APS. All other groups were made up of six animals. Values are means ± SD.
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Comparison of BABIM and BBE
From the studies just discussed, BABIM and BBE
emerged at opposite ends of the spectrum of inhibitory
activities. BABIM excelled as inhibitor of synovitis, but
was ineffective in controlling granulomatous splenitis. The
converse was true for BBE. There was a certain sharing
of common ground in that both compounds were able to
reduce the severity of the osteitis. To further delineate
their behavior and possible usefulness, a series of exper-
iments was carried out.
To judge the absolute potency of BBE, the same
5-day test used to obtain the data for Table 2 was re-
peated with reduced amounts of BBE. As shown in Table
3, a 5-mg dose completely suppressed granuloma for-
mation in the spleen, and even a 2.5-mg dose had a
significant effect. BABIM again did not alter the splenitis,
although it produced a mild reduction in spleen weight.
In the next series of experiments, the duration was
extended to 14 days. This was done to judge the effect of
the inhibitors on granulomatous hepatitis, a lesion that
begins to develop approximately 9 days after PG-APS
injection.2 In one set of animals, treatment was in a cura-
tive fashion, i.e., the disease was allowed to proceed for
1 week, and then either BABIM or BBE were given during
the second week. In another group of animals, treatment
with BBE was in a preventive mode, i.e., it was started at
the same time that PG-APS was administered. The influ-
ence on the joint and bone changes is presented in Table
4, whereas the findings in liver and spleen are incorpo-
rated in Table 5.
From the data in Table 4, it is evident that at the time
of sacrifice, the control animals had severe synovitis and
osteitis. The distal tibial metaphysis and epiphysis had
lost all trabecular bone in a process of neutrophil-
assisted osteoclasia,2 and the hollowed-out space was
filled in by granulation tissue (Figure 1 A). The epiphyseal
plate was fragmented or missing. In animals that had
received BABIM during the second week, there was a
modest lessening of the synovitis and osteitis, and an
abortive attempt at healing in the epiphysis and metaph-
ysis as indicated by early new bone formation (rated as
Reparative Bone Score) occurred. In the group that had
been supplied with BBE during the second week, there
was no improvement in the severity of the synovitis, but
there was clearing of all active osteitis and the metaphy-
seal/epiphyseal defects had already been completely
filled in with new trabecular bone (Figure 1 B). In the treat-
ment group that had been given BBE throughout both
weeks, there was some improvement in the synovitis, but
more impressive was the total absence of any lesion in
the bone and thus also of the need for a reparative pro-
cess (Figure 1C).
The data on liver and spleen for the animals just dis-
cussed are also instructive (Table 5). In the vehicle-
treated controls, PG-APS application brought about a
2.4-fold increase in liver weight and a 7-fold increase in
spleen weight as compared with non-PG-APS-treated
controls (footnote, Table 5). In the liver parenchyma nu-
merous macrogranulomata were present. They are de-
fined as lesions whose diameter exceeds [fr 1/2] high-
power field at x 450. The majority of the granulomata
contained central collections of neutrophils often associ-
ated with necrosis (Figure 2A). In the spleen of these
control animals, there were large confluent granuloma-
tous lesions with a geographic pattern (Figure 2B). More
than two-thirds of the parenchyma was thus afflicted. As
can be seen in Table 5, BABIM treatment during the sec-
ond week did not significantly alter any of the liver or
spleen parameters studied. BBE treatment during the
same period, however, efficiently limited weight gain of
liver and spleen. There was a reduction in the number of
hepatic macrogranulomata, which was statistically signif-
icant if the organ-weight differential against the controls
was taken into consideration. The size of the area of ne-
crosis and granulomatous inflammation in the spleen was
held to 11.5% compared with 68.3% in the controls. The
2-week course of BBE application also controlled organ
Table 3. Effect ofReduced Doses ofBBE on Synovitis, Tibial Osteitis, and Spleen Weight and Splenic
Granulomatous Inflammation
Treatment* Spleent
Daily dose Synovitis Tibial osteitis Weight Granuloma
Inhibitor mg/kg b.w. score 0-8 score 0-4 mg/100 g b.w. score 0-4
None 2.63 0.59 1.42 + 0.86 816 ± 48 1.93 ± 0.59
BABIM 10 0.38 0.47t 0 670 ± 105"1 2.48 ± 1.03
BBE 5 2.75 ± 0.63 0.63 ± 0.97 428 ± 32"1 0
BBE 2.5 2.83 ± 0.88 0.87 ± 0.71 560 ± 67t 0.57 ± 0.59¶
* Groups of six animals each received PG-APS and five consecutive daily doses of inhibitor in the amounts stated. The animals were
sacrificed 1 day after the last injection. All values are means ± SD.
t The spleen weight of rats that had received neither PG-APS nor inhibitor was 232 ± 8 mg/100 g b.w. (n = 4).
t P < 0.0001 against vehicle-treated controls.
P < 0.05 against vehicle-treated controls.
¶ P < 0.005 against vehicle-treated controls.
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Table 4. Synovitis, Tibial Osteitis, and Reparative New Bone Formation 2 Weeks after PG-APS Injection: Effect ofDelayed
Treatment with Either BABIM or BBE and of Uninterrupted ab initio Treatment with BBE
Treatment* Tibia
Daily dose mg/kg b.w.
Synovitis Osteitis Reparative bone
Inhibitor 1 st week 2nd week score 0-8 score 0-4 scoret 0-4
None 2.60 ± 1.12 3.30 ± 0.27 0
BABIM 10 1.83 ± 0.90 2.25 ± 1.70 0.50 ± 0.84
BBE 10 2.97 ± 0.72 0.08 ± 0.20t 4
BBE 5 5 1.43 ± 1.11 0 0
* n = 6 for all groups. Values are means ± SD.
t Degree of healing by new bone formation.
t P < 0.001 against vehicle-treated controls.
weights and prevented appearance of any macrogranu-
lomata in the liver and of any necrotic lesions in the
spleen. A surprise finding, however, was the presence of
numerous hepatic and splenic microgranulomata in both
BBE series (Figure 2C, D). They will be further discussed
in the following section.
BBE-induced Changes in Macrophage
Morphology
After its injection into the peritoneal cavity, PG-APS is
taken up by macrophages that rapidly gain access to the
general circulation. Within a few hours those cells can be
identified in the ramifications of the portal venous system,
and the streptococcal cell-wall fragments will appear in-
creasingly in the Kupffer cells. At the same time, notice-
able accumulation of the material in splenic macro-
phages occurs, initially mainly in the marginal zone, but
later on also in the periphery of the red pulp. In animals
that have received PG-APS only or PG-APS as well as
BABIM, the PAS-positive deposits in the macrophages in
liver and spleen appear in finely granular form (Figure 3A,
B). In animals that have been treated with BBE, however,
the macrophages in both organs take up excessive
amounts of PG-APS. The cells become massively en-
larged and the granules fuse (Figure 3C, D). The abun-
dance of the PAS-positive deposits imparts a glossy, lac-
quered quality to the cytoplasm. In animals that have
been treated with BBE for 14 days, but less so in those
treated for only 7 days, the overstuffed hepatic and
splenic macrophages appear to have a tendency to
burst and release some of the PG-APS. This, in turn,
leads to attraction of monocytes from the circulation
which ingest the material and aggregate in groups, con-
siderably smaller than the macrogranulomata (Figure 2C,
D).
The unexpected discovery of the microgranulo-
mata-by definition lesions with a diameter of less than [fr
1/2] high power field at x 450-in animals still under BBE
protection raised the question if discontinuation of treat-
ment would cause transformation of the aggregates into
full-blown macrogranulomata with accompanying neu-
trophilic infiltration and necrosis. Similarly, one might won-
der about a possible late recrudescence of the joint and
bone lesions. To obtain an answer, rats were given daily
injections of either BABIM or BBE for 1 week and were
then allowed to survive for 18 additional days without fur-
ther treatment. The results are summarized in Table 6
and Table 7, for synovium and bone, and liver and
spleen, respectively. In the drug-free controls, active syn-
ovitis and severe destructive osteitis with little evidence of
Table 5. Hepatic and Splenic Granulomatous Disease 2 Weeks after PG-APS Injection: Effect ofDelayed Treatment with
BABIM or BBE and of Uninterrpted ab initio Treatment withBBE
Treatment* Livert Spleent
Daily dose (mg/kg b.w.) Macro- Micro- Necrosis
Weight granulomata granulomata Weight % of cut
Inhibitor 1st week 2nd week mg/100 g b.w. no./100 mm2 no./100 mm2 mg/100 g b.w. surface
None - 9,572 1,575 58 41 77 13 1,756 256 68.3 8.7
BABIM 10 9,158 1,485 52 34 63 27 1,484 259 63.3 9.8
BBE 10 6,087 ± 58111 24 ± 31 208 ± 24 520 ± 16011 11.5 ± 10.511
BBE 5 5 5,561 ± 622"1 0 926 ± 266 755 ± 157"1 0
* n = 6 for all groups. Values are means ± SD.
t The liver weight of rats that had received neither PG-APS nor inhibitor was 3,931 ± 281 mg/100 g b.w. (n = 4).
t The spleen weight of rats that had received neither PG-APS nor inhibitor was 250 ± 45 mg/100 g b.w. (n = 4).
"P < 0.0005 against vehicle-treated controls.
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Table 6. Synovitis, Tibial Osteitis, and Reparative New Bone Formation 25 Days after PG-APS Injection: Effect of Initial
1-Week Treatment with either BABIM orBBE
Treatment* Tibia
Daily dose Synovitis Osteitis Reparative bone
Inhibitor mg/kg b.w. score 0-8 score 0-4 score 0-4
None 2.68 ± 1.08 3.44 ± 0.61 1.06 ± 1.05
BABIM 10 1.74 ± 1.40 2.75 ± 1.00 0.69 ± 1.03
BBE 5 0.89 ± 1.28t 0 0
* n = 8 for all groups. Values are means ± SD.
t P < 0.05 against vehicle-treated controls.
bone repair occurred. Liver weights and extent of gran-
ulomatous involvement were about the same as at the
end of the earlier 2-week experiment (Table 5). However,
healing of the granulomata by scarring had begun. The
spleens in these controls were considerably smaller than
at the 2-week mark because of removal of much of the
necrotic debris. All viable splenic red pulp was densely
packed with trilineage hemopoietic elements. A glance at
the data for BABIM shows that the compound caused
slight improvement in synovitis and osteitis (Table 6), but
had no effect at all on liver and spleen (Table 7). BBE
application, on the other hand, led to maintenance of a
significant suppression of synovitis, preserved the integ-
rity of the tibial bone, and almost completely protected
liver and spleen. Even after the 18-day drugfree period,
the livers were without macrogranulomata, and the mi-
crogranulomata were small in number. As to the spleen,
the histologic appearance was normal, i.e., there were
neither granulomata nor hemopoietic elements.
Finally, the distribution of PG-APS in the macrophages
can be altered secondarily. In the experiment in which
the rats received BBE only in the second week, for ex-
ample, the intracytoplasmic deposits in the macro-
phages during the first week would have been in the
finely granular form. However, when the animals were
killed after the second week, the macrophages in liver
and spleen showed the typical BBE effect, i.e., massive
enlargement.
Figure 2. Sections of rat liver (AC) and spleen (B,D) two weeks after systemic injection ofPG-APS. Vehicle-treated rats: A Hepatic macro-
granuloma with central necrosis and neutrophilic infiltrate. B. Confluent necrotizing granulomatous inflammation in the spleen. BBE-
treated rats (5 mg/kg body weight/day): C. Hepatic microgranuloma without necrosis or neutrophils. D. Splenic microgranulomata without
necrosis or neutrophitls (H&E; A and D, x175; B, X88; C, X350).
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Figure 3. Streptococcal cell wall deposits in rat Kupffer cells (AC) and splenic macrophages (B,D)5 days after systemic PG-APS injection. A,B:
Small size ofKupffer cells and splenic macrophages, respectively, in vehicle-treated animals. C,D: Massive enlargement ofKupffer cells and
splenic macrophages, respectively, in animals which had received BBE in the daily dose of 10 mg/kg body weight. Arrows point towards the
Kupffer cells and splenic macrophages, respectively. (PAS stain, x 525).
Discussion
Study of the antiinflammatory properties of BABIM deriv-
atives has revealed not only a significant variation in po-
tency of the individual compounds but also a surprising
qualitative difference in the inhibitory spectrum. At one
end, there is BABIM, which is active chiefly against syn-
ovitis and tibial osteitis and is most effective in a preven-
tive role. At the other end, there is BBE, which excels in
the suppression of splenic and hepatic granulomatous
disease and also of tibial osteitis, and which is able to act
in a preventive as well as curative mode. The divergent
behavior of the compounds argues for different points of
interaction, i.e., interference with an early reaction se-
quence for BABIM and blockage of a continually ongoing
reaction for BBE. The effectiveness of BABIM when given
from the beginning of the disease and its failure when
started late, cannot be attributed to the more acute nature
of the inflammation in the early stages and its more
chronic nature in the late stages, because when given
preventively without interruption, the compound has
been effective in acute as well as chronic synovitis.
The histologic changes in splenic and hepatic mac-
rophages clearly single out those cells as targets of BBE,
and so far all other compounds with the ability to block
splenic granuloma formation have shown a similar pro-
clivity to cause macrophage enlargement. However, in-
creased storage of PG-APS itself is not the proximate
cause of the antigranulomatous effectiveness of a given
compound. This is known because several benzimida-
zoles, such as numbers 5 and 7, produce bloating of the
cells but do not inhibit granuloma formation.
Table 7. Liver and Spleen Weights and Hepatic Granulomata 25 Days after PG-APS Injection: Effect of Initial 1-Week
Treatment with either BABIM orBBE
Treatment* Livert Spleent
Daily dose Weight Macrogranulomata Microgranulomata Weight
Inhibitor mg/kg b.w. mg/100 g b.w. no./1 00 mm2 no./1 00 mm2 mg/100 g b.w.
None 10,778 914 68 15 4 ± 2 629 ± 153
BABIM 10 9,662 1,235 60 22 4 ± 3 643 ± 444
BEE 5 4,475 219t 0 49 ± 12 302 ± 23t
* n = 8 for all groups. Values are means ± SD.
t The liver and spleen weights in rats that had received neither PG-APS nor inhibitor were 3,893 ± 66 mg/i 00 g b.w. and 204 ± 18 mg/i 00
g b.w., respectively (n = 4).
t P < 0.0001 against vehicle-treated controls.
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Currently, how BBE might stimulate the massive de-
position of PG-APS in splenic and hepatic macrophages
is uncertain. Accelerated production of cell-surface re-
ceptors, enhanced numbers of phagosomes, imped-
ance of phagolysosome fusion, and a reduction of the
release of stored material are mechanisms to be consid-
ered. Electron microscopic methods are being employed
to investigate those possibilities. The appearance of
bloated macrophages is also influenced by the microen-
vironment. Though PAS-positive macrophages are en-
countered in the inflamed synovium and tibial marrow,
no giant forms have been identified in those locations.
It has been shown that the microgranulomatous reac-
tion to rupture of PG-APS-laden macrophages in BBE-
treated animals does not proceed to a macrogranuloma-
tous response, even if treatment is halted. There are at
least two possible explanations for such a favorable out-
come. First, the ingested PG-APS might be so modified
within the macrophages that, when released, it does not
evoke the complete macrogranulomatous event. Sec-
ond, BBE might be retained in the tissues or macro-
phages for a prolonged period of time and might thus
exert a continuous restraining influence on the inflamma-
tory process. Although the second hypothesis is favored
at this point, detailed pharmacokinetic investigations will
be needed to prove its validity. Regardless of the out-
come of such a study, it is believed that microgranulo-
mata in the aftermath of BBE treatment will generally heal
without permanent damage.
In view of the ability of BABIM and its congeners to
inhibit trypsinlike enzymes, blockage of such proteases
might account for the beneficial effect of the compounds
on PG-APS-induced inflammation. However attractive the
idea was, it could not be supported by the findings of this
study. The data in Tables 1 and 2, as discussed in the
Results section, have already removed trypsin and
thrombin from consideration as targets. This brings up
urokinase-type plasminogen activator (UK) as another
likely candidate for inhibition. UK is a secretory product of
stimulated macrophages.15'16 It transforms plasminogen
into plasmin which in turn is able to hydrolyze fibrin, to
split a variety of proteins, such as basement membrane
components, to stimulate release of interleukin 1 from
monocytes, and to activate other enzymes, including
procollagenase.81017 UK thus plays a prominent role in
acute and chronic inflammation. If the antigranulomatous
effect of BBE were directed against UK, its Ki value for the
enzyme should have been lower than with BABIM. In fact,
however, the converse was true BBE having a Ki value of
1.15 x 10-5 M and BABIM of 2.33 x 10-6 M. UK inhi-
bition could also not be tied to antisynovitis potency. This
derives from the fact that compound number 7 and com-
pound number 8 had nearly identical K, values against
UK (1.42 x i0-4 M and 1.72 x 10-4 M, respectively),
and still the former compound was a competent inhibitor
of synovitis, whereas the latter was completely ineffective.
Similar arguments can be brought forward against plas-
min inhibition playing a role in successful treatment. The
antigranuloma agent BBE again was a weaker inhibitor
than the antisynovitis agent BABIM (Kj 7 x 1 0-5 M ver-
sus 2.65 x 10-6 M, respectively), and the potent anti-
synovitis agent number 2 had a Kj value not greatly dif-
ferent from the inactive agent number 8 (3.92 x 10-5 M
versus 5.23 x 10-5 M, respectively).
In several respects, the immunosuppressive agent
cyclosporine A (CsA) has a similar effect as BBE on PG-
APS-induced disease. It completely prevents granuloma
formation in the liver and reduces the severity of the
chronic arthritis, but it has no apparent influence on the
acute phase of the joint inflammation.18 Those findings
raise the question if the two drugs might not also share
the same mode of action. Since CsA has well-defined
immunoregulatory properties involving T lymphocytes
and macrophages,1-20 BBE could be tested for those
same characteristics to establish or to disprove a func-
tional relationship between the two agents.
At this point, it is undetermined if the power of BBE to
suppress granulomatous reactions is restricted to PG-
APS-induced lesions or if it also applies to granulomata
from other causes. Should the latter be true, the com-
pound might be considered for treatment of such immu-
nologically mediated, noninfectious granulomatous con-
ditions as sarcoidosis and Crohn's disease.
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